Previous 10 | Next 10 |
Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update PR Newswire MARLBOROUGH, Mass., Nov. 10, 2020 MARLBOROUGH, Mass. , Nov. 10, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company ...
Beyond Meat (BYND) -23% on Q3 earnings release.InnSuites Hospitality (IHT) -20%.Jumia Technologies (JMIA) -19% on Q3 earnings release.Aurora Cannabis (ACB) -13%.Applied UV (AUVI) -13%.GasLog Partners (GLOP) -13% on Q3 earnings release.Waitr Holdings (WTRH) -...
Phio Pharmaceuticals (PHIO) jumps 22% premarket after in reaction to positive data from an in vivo study that shows the strong antitumoral efficacy of individual INTASYL pipeline products, including PH-762, PH-790 and PH-804.These data were presented during The Society for Immu...
Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment The new data was presented at the SITC 2020 Virtual Scientific Program PR Newswire MARLBOROUGH, Mass., Nov. 9, 2020 ...
Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting PR Newswire MARLBOROUGH, Mass., Oct. 26, 2020 MARLBOROUGH, Mass. , Oct. 26, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (N...
MARLBOROUGH, Mass. , Sept. 9, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced ...
Phio Pharmaceuticals (NASDAQ: PHIO ) : Q2 GAAP EPS of -$0.34 beats by $0.31 . More news on: Phio Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, , Read more ...
MARLBOROUGH, Mass. , Aug. 12, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its fin...
Hexindai (NASDAQ: HX ) -14% . More news on: Hexindai Inc., Phio Pharmaceuticals Corp., Centogene N.V., Stocks on the move, , Read more ...
ITeos Therapeutics ( ITOS ) has filed a preliminary prospectus for a $100M IPO. More news on: Roche Holding AG, Phio Pharmaceuticals Corp., Agenus Inc., Healthcare stocks news, IPO News, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Phio Pharmaceuticals Corp. Company Name:
PHIO Stock Symbol:
NASDAQ Market:
Phio Pharmaceuticals Corp. Website:
Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells...
Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to ...
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced i...